ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. - Wikidata - wikimedia - TriplyDB

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

http://www.wikidata.org/entity/Q34202155

about

Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies Next-generation surveillance strategies for patients with lymphoma A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.Hodgkin lymphoma, version 2.2015.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.ABVE-PC and modified BEACOPP regimen in Indian children with Hodgkin lymphoma: Feasibility and efficacy Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Advanced hodgkin lymphoma: a new era of therapy.Hodgkin disease-an ever-evolving therapy.Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks Hodgkin lymphoma.Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma.Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma.FDG-PET/CT based response-adapted treatment.Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.Systemic cancer therapy: achievements and challenges that lie ahead Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience.Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.Management of children with high-risk Hodgkin lymphoma.Hematological cancer in 2011: New therapeutic targets and treatment strategies.State of the art in the treatment of Hodgkin lymphoma.Novel agents in Hodgkin lymphoma.Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management.The role of monoclonal antibodies in the treatment of lymphomas.Classical Hodgkin's lymphoma: past, present and future perspectives.Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives.

P2860

Q26830130-A43C6C3A-24DB-4E6D-BB8C-A84E580D578C Q28084956-08F5B293-22F7-4782-8609-D24A52D07B61 Q30538453-8044C3BF-E955-4D4F-8285-70690ABCDCC6 Q30769157-6061D8BD-8F08-48D9-A4E8-F0B22A309551 Q33411127-A089CB9C-22FE-4E4B-A41A-A8BA5F2A3AB4 Q33432165-CB120444-005D-4CEA-84B1-84EC279815CD Q33442092-E3FEDE8D-80D5-48A4-ACC3-BE91FE17E749 Q33704061-07F135AE-440D-4CE1-B9BB-CA255E928656 Q34194160-07775283-5EF3-4DAF-85CB-AA865DCCEDF5 Q34463426-F2C96882-2927-4777-A5EA-10A1F4D7FF31 Q34610653-7B7DE989-7FF1-4468-A28A-D70CF839EEC7 Q34639390-30C8C6DB-1F09-4720-AC80-02A4C0FB53AE Q34640709-5761588D-CD0E-4FE4-A0D0-F0B6B3BCA60C Q34643277-2998C5F0-CCA7-42EA-829C-A285A50EAA5A Q34645722-D06CC402-41E5-465E-9CA5-F0B3100B2E6F Q34662648-0741412E-C5BA-4B79-8498-F98D171411D0 Q34664223-12DA4C61-A27B-494E-B8D0-6E724010854C Q35103531-926CEBE0-3ED0-4DF7-822B-693BD01E499D Q35669134-4E815B6D-0615-4A97-83AC-6DFFEAFFC423 Q35763914-44A2F387-4D1E-4D90-B381-8A3AB2C93B5F Q35986604-1F400AB5-3207-4EE9-AAF7-6938133DA1B6 Q36164491-7D45E485-5E76-488B-B578-CD2B80172463 Q36286595-DEDE388D-1802-41B8-888B-92D13836DBD7 Q36371623-6679AC4C-E688-4548-A340-0EE0B101FB24 Q36615084-10EE69B8-22F8-4EAD-8932-6D7DAE578512 Q36821958-B94EAB23-71C0-461C-AE04-F5F108BF3BA4 Q36939926-12AA0A4C-A8C6-401D-BAAF-7DB5C414C0FC Q37091269-5B8D0185-4653-43E8-B9B5-9705F64BE2BE Q37126978-7B948C2D-AD5D-4CA5-A9AD-9D554EF5D130 Q37563122-0D930F1C-DD14-45D1-BE3A-E93668B99700 Q37659012-7FE6E9D3-BCE0-417E-9180-DE1C6313F1D8 Q37970408-354C0628-D313-4E1A-AB45-6FA26F45207B Q37974569-7A21AA95-C81F-43D9-87C5-B00459CBEB85 Q38017914-5E0C5409-F59F-4FA3-B2B9-674ADD74FFD3 Q38019429-6306704B-B544-4340-B04B-4F44BAFEAF62 Q38059817-66A60847-AC65-493D-9031-2D302DC36D03 Q38069595-65B0ACD4-F081-4026-AE59-F3902766CC7B Q38162057-A538FF1A-EC83-4102-BDB5-D8A214438DA9 Q38164572-848D9142-9BB4-4623-A419-0728D832F6FE Q38205880-EEC091A3-7B34-4DD2-A4AC-ED6C89FD5F3B

P2860

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

http://www.wikidata.org/entity/Q34202155

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

@ast

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

@en

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

@nl

type

label

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

@ast

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

@en

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

@nl

prefLabel

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

@ast

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

@en

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

@nl

P1433

Q34202155-262AF8A5-C700-427E-BE9D-A01FD7C9852A

P1476

Q34202155-E5E88AEC-A1F5-4356-82F0-C44727266A7B

P2093

Q34202155-1E416C46-F58A-4240-B641-F8016CF9810A

Q34202155-335C415E-7BD4-47AD-830B-803A19FF8294

Q34202155-53162776-D2B0-4E49-B9D1-8525FF177494

Q34202155-534D1593-74B7-42D1-84CC-3DDFEE2CEF1B

Q34202155-584EB6FC-4E9D-4BE5-B5E3-EC436DFD4D9E

Q34202155-5DAECC2A-DDDF-4D7E-920E-017D9C56B047

Q34202155-71E3EC7C-99E8-48D6-A1D1-EB665887CDE7

Q34202155-919FE462-672D-4C6A-B113-B13B69D43C54

Q34202155-BFCBC4BE-F6D9-4DDB-A521-0D84D8B989D2

Q34202155-C1136346-17B8-403C-88A9-D425DA257F17

P304

Q34202155-F2BEBC57-8F16-455C-ACFA-4E6380CCF950

P31

Q34202155-90A14A0A-1145-4304-B6E7-A77750091A11

P356

Q34202155-DADD64BA-378A-4C6D-AE85-BF22BD7EBDA6

P407

Q34202155-87A9B8D2-8F19-4C91-87FB-6862A20551C0

P433

Q34202155-E5D7FD97-CEA7-40FA-8A1B-F5A2319E72EC

P478

Q34202155-1872998A-706E-4046-9375-D61C468C43B0

P50

Q34202155-934438F4-4DA0-43BA-85E9-8BB0A9A0D8DE

Q34202155-B47E5034-30BD-4678-843C-D9E10E531344

P577

Q34202155-31D6A2BB-B883-4CEB-8520-A572866E6235

P698

Q34202155-30E0D86E-00CE-4C98-B5C7-216D18B18E35

P356

P1433

The New England Journal of Medicine

P1476

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

@en

P2093

Alessandro Levis

http://www.w3.org/2001/XMLSchema#string

Alessandro M Gianni

http://www.w3.org/2001/XMLSchema#string

Alessandro Pulsoni

http://www.w3.org/2001/XMLSchema#string

Alessandro Rambaldi

http://www.w3.org/2001/XMLSchema#string

Andrea Gallamini

http://www.w3.org/2001/XMLSchema#string

Andrea Rossi

http://www.w3.org/2001/XMLSchema#string

Anna Marina Liberati

http://www.w3.org/2001/XMLSchema#string

Delia Rota Scalabrini

http://www.w3.org/2001/XMLSchema#string

Enrico M Pogliani

http://www.w3.org/2001/XMLSchema#string

Ercole Brusamolino

http://www.w3.org/2001/XMLSchema#string

P304

203-212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1100340

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

365

http://www.w3.org/2001/XMLSchema#string

P50

Pinuccia Valagussa

Pier Luigi Zinzani

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21774708

http://www.w3.org/2001/XMLSchema#string